Citius Pharmaceuticals Inc (NASDAQ:CTXR) IP Improvements Could Help to Spark a Resurgence

 

 
info@mybeststockpicks.com 1-(844)-30-STOCK  
To Get Update On Mobile Text STOCKS to 67076
The #1 Newsletter for Highly Profitable Penny Stock Alerts
Our new pick is CTXR

Good Morning Traders, 

Citius Pharmaceuticals Inc (NASDAQ:CTXR) shares have been forming what could be an extremely important bullish basing pattern following a “puke” of weak-handed investors and traders in early August. This small-float stock has been climbing along the 50-day simple moving average. A break above this benchmark level could spark a potential major influx of new interest.

To help spur this shift, the company just announced that it has received official notification from MD Anderson Cancer Center that the European Patent Application for Mino-Lok with Enhanced Stability was published under serial number 3370794. According to the release, “This patent which already received a Notice of Allowance from the US Patent and Trademark Office in July of 2018, and which patent was issued by the USPTO earlier this month, will provide and strengthen intellectual property protection for Mino-Lok through November of 2036.”

Citius Pharmaceuticals Inc (NASDAQ:CTXR) frames itself as a specialty pharmaceutical company that develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, and prescription products. 

The company develops Mino-Lok product, which has completed Phase IIb clinical trials for the treatment and salvage of infected central venous catheters in patients with catheter related bloodstream infections; and Hydro-Lido product, a topical formulation of hydrocortisone and lidocaine that is intended for the treatment of hemorrhoids.

It has a collaboration and license agreement with Alpex Pharma S.A. to develop and commercialize orally disintegrating tablet formulations of pharmaceutical products in United States, Canada, and Mexico. 

Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.

According to company materials, “Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives, cancer care and unique prescription products that use innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. Citius develops products that have intellectual property protection and competitive advantages to existing therapeutic approaches.”

Securing Boundaries

As noted above, the company just announced that it has received official notification from MD Anderson Cancer Center that the European Patent Application for Mino-Lok with Enhanced Stability was published under serial number 3370794.

The chart shows 9% added to share values of the stock over the past month of action. Furthermore, the listing has seen a growing influx of trading interest, with the stock’s recent average trading volume running 11% over what the stock has registered over the longer term. 

This should not be overlooked given the stock’s tiny trading float of 4.5M shares. It’s something the veterans know to key on: ramping trading activity can overwhelm available supply in a stock with this type of small float, leading to an upward burst in prices.

“The protection of company’s intellectual property is vital and enhanced post-reconstitution stability of the Mino-Lok is a very important innovation,” said Mr. Myron Holubiak, President and CEO of Citius Pharmaceuticals. “This will enable standard pharmacy process to be employed in the delivery of Mino-Lok to the patient and would allow for several days’ storage of ready-to-use Mino-Lok. This new European patent will provide us broader protection in the major markets of the world for our new formulation.”

Now commanding a market cap of $26.08M, CTXR has a significant war chest ($2.8M) of cash on the books, which compares with about $2.2M in total current liabilities. The company is pre-revenue at this point, but this is an extremely exciting story, and we look forward to a follow-up chapter as events transpire.

Don’t forget to try our Free Easy-to-Use SMS service for real-time alerts and winning tips. Simply send the message STOCKS to the number 67076.

 

Best Regards,

 

 

DISCLAIMER

The disclaimer is to be read and fully understood before using our site Mybeststockpicks.com also refered to as MBSP. This report/release/video profile is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below. Never invest in any stock discussed on Mybeststockpicks.com or MBSP’s newsletter unless you can afford to lose your entire investment. Never listen to anyone on MBSP message boards or private messages sent by any user or member who offers any sort of financial advice. Please consult with a certified financial advisor before making any investment decisions. MBSP and any affiliates and information providers make no implied or expressed warranties on the information provided. Please verify quotes with your investment manager before making investment decisions. This is not to be construed as a solicitation to buy or sell securities. Any stock or featured companies on MBSP web site and/or newsletter involves a high degree of risk and volatility, and all investors should know that they may lose a portion or all of their investment if they decide to purchase any stock mentioned or talked about on MBSP or message boards. MBSP makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or members and does not guarantee the correctness, completeness or quality of information and statements presented on MBSP. Any such information or statements should be deemed apocryphal and opinions only. Neither MBSP, nor any of its affiliates, are registered investment advisors or broker dealers and do not make recommendations to buying, holding, or selling of any securities. MBSP simply provides a starting point for site members and viewers to compare their own thoughts against those here on the message boards at MBSP. The onus is on site members and viewers to complete their own due diligence. MBSP members and viewers should always make their own financial decisions. The accuracy and completeness of the information within any report, newsletter or on website message boards is only as reliable as the information that is provided by MBSP members and users. MBSP does not verify the information, and makes no warranty that the information is accurate. MBSP members, readers and viewers are cautioned that small and micro-cap stocks are high-risk investments and that all investment dollars can be lost. We suggest you consult a professional investment advisor before purchasing any stock. All opinions and postings expressed on MBSP web site are the opinions of MBSP members and users . All information concerning any company is provided by the members and users that create the information box on each board. MBSP recommends you use the information found here on the site and boards as an initial starting point for conducting you own research and conduct your own due diligence (also known as “DD” on any company you read about here at MBSP, in order to determine your own personal opinion of the company before investing in these or any other companies. MBSP assumes all information to be truthful and reliable. However, we cannot and do not warrant or guarantee the accuracy of this information. MBSP is NOT an Investment Advisor, Financial Planning Service or a Stock Brokerage Firm and in accordance with such MBSP is not offering investment advice or promoting any investment strategies. MBSP is not offering securities for sale or solicitation of any offer to buy or sell securities. An offer to buy or sell can be made only with accompanying disclosure documents and only in the states and provinces for which they are approved. On occasion, MBSP may receive compensation from a third party in relation to the companies being profiled in its Newsletters sent to our members. In such a case MBSP directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation.  in relation to the companies being profiled in its Newsletters sent to our members. In such a case MBSP directly mentions such compensations at the bottom of this disclaimer along with the exact form and amount of compensation.  Mybeststockpicks has been compensated total of two thousand dollars by ALG Financial to perform 1 week investors awareness advertisement on XSPL

.  Do your own research and due diligence before investing in any company. MBSP merely is providing information and is in no way or manner suggesting an investment in any company or investment opportunity. You are the investor and are making decisions for yourself. report/release/video profile is a commercial advertisement and is for that purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation unless otherwise stated below.

 

2012 www.mybeststockpicks.com. All rights reserved.
Total Views: 1524 ,